Cardiovascular Disease in CKD Patients: Pre-Dialysis and Dialysis

This is continuing education for the medical profession. If you would like to read more and see the slides with audio go to http://www.medscape.com/viewprogram/17144_pnt

Cardiovascular Disease in CKD Patients: Pre-Dialysis and Dialysis CME/CE
Mark J. Sarnak, MD, MS, Program Chair; David A. Bushinsky, MD; Charles A. Herzog, MD

Complete author affiliations and disclosures are at the end of this activity.

Release Date: September 9, 2008; Valid for credit through September 9, 2009

Target Audience
This activity is designed for physicians, physician assistants, nurses, nurse practitioners, dietitians, dialysis technicians, pharmacists, social workers, and other health care professionals who care for people with chronic kidney disease (CKD).

Goal
Cardiovascular (CV) disorders are a major cause of morbidity and mortality in patients with chronic kidney disease (CKD), and sudden death is the leading cause of CV mortality in dialysis patients. Elevated serum phosphorus and calcium concentrations are associated with increased risk of CV events and death in patients with end-stage renal disease. The purpose of this activity is to discuss how appropriate screening and therapy can help minimize the impact of heart disease in these patients and to examine the link between elevated phosphorus and calcium levels and CV disorders in patients with CKD. This presentation will also explore the epidemiology of sudden death in patients on dialysis, the most appropriate therapies for established coronary artery disease in these patients, and how different phosphate binders may affect clinical outcomes in this population. The role of screening for coronary artery disease in asymptomatic CKD patients will also be examined.
Learning Objectives
By completing this activity, participants should:

1. Learn about the epidemiology of sudden death and possible interventions in dialysis patients.
2. Learn about the cardiovascular effects of calcium and phosphorus.
3. Learn about the controversies on coronary artery disease screening and therapy in CKD.

Credits Available
Physicians - maximum of 2.0 AMA PRA Category 1 Credit(s)™ for physicians;
Family Physicians - up to 2.0 AAFP Prescribed credit(s) for physicians;
Nurses - 2.0 ANCC contact hours;
Pharmacists - 2.0 ACPE continuing education credits for pharmacists (0.2 CEUs)

All other healthcare professionals completing continuing education credit for this activity will be issued a certificate of participation.

Physicians should only claim credit commensurate with the extent of their participation in the activity.
Accreditation Statements
Learning Objectives
By completing this activity, participants should:

1. Learn about the epidemiology of sudden death and possible interventions in dialysis patients.
2. Learn about the cardiovascular effects of calcium and phosphorus.
3. Learn about the controversies on coronary artery disease screening and therapy in CKD.

Authors and Disclosures

Mark J. Sarnak, MD, MS
Disclosure: Grant/Research Support: Amgen

David A. Bushinsky, MD
Disclosure: Consultant: Amgen, Genzyme, Ilypso, Relypsz, Shire; Speakers’ Bureau: Amgen, Genzyme, Ilypso, Relypsz, Shire; Stockholder: Amgen

Charles A. Herzog, MD
Disclosure: Grant/Research Support: Amgen, AstraZeneca, Medtronic, NIH; Consultant: Amgen, CorMedix, Guidant, Medtronic, Ortho Biotech, Roche; Board of Trustees Member: RoFAR

For Physicians

nkf

The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Kidney Foundation designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity has been reviewed and is acceptable for up to 1.75 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 8/1/08.

This activity is applicable for Category 2-B Credit through the American Osteopathic Association for Doctors of Osteopathy.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity: cmeinfo@kidney.org. For technical assistance, contact CME@webmd.net.

For Nurses

The National Kidney Foundation is an approved provider of continuing nursing education by the New York State Nurses Association, which is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

It has been assigned code 6EXQ7J-PRV-O6.

This educational activity is approved for 2.0 contact hours.

Physician Assistant:
AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit(s)TM for the PRA from organizations accredited by ACCME.

Nurse Practitioner:
This program has been approved for 2.0 contact hours of continuing education by the American Academy of Nurse Practitioners. Program ID 0806293.

CDRRegistered dietitians (RDs) and dietetic technicians, registered (DTRs):
CPEs Awarded: 2.0; Level 2.0

The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR).

CDR Accredited Provider Number: NK111

Social Worker:
The National Kidney Foundation Council of Nephrology Social Workers, Provider #1014, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org, through the Approved Continuing Education (ACE) program. The National Kidney Foundation Council of Nephrology Social Workers maintains responsibility for the program. Social workers participating in this course will receive 2.0 continuing education clock hours. Licensed social workers should contact their individual jurisdiction to review current continuing education requirements for licensure renewal.

For Pharmacists
ACPE logo

The University of Missouri-Kansas City, School of Pharmacy, is approved by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. The ACPE universal program number assigned to this educational offering is 034-999-08-018-H01-P.

This program is accredited by the University of Missouri-Kansas City for 0.2 CEUs (2.0 contact hours).

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity: BrownW@umkc.edu. For technical assistance, contact CME@webmd.net.
Instructions for Participation and Credit
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. Participants should read the overview, learning objectives, disclosures and view the slide presentation with accompanying audio in its entirety. After viewing the presentation, you will be asked to complete the post-test and program evaluation. Please be sure to fill these out completely and your certificate will be available for you to print out. A minimum score of 75% is required for certification.* If you do not pass the test, you may retake it. The estimated time for completion is 2.0 hours.You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.*The credit that you receive is based on your user profile.

This activity is supported by an educational grant from Genzyme Renal.

TO VIEW THE ACTIVITY GO TO http://www.medscape.com/viewprogram/17144_pnt